YAMATO Study (Tissue-Type Plasminogen Activator and Edaravone Combination Therapy)

Area of Science:

• Neuroscience
• Pharmacology
• Emergency Medicine

Background:

• Stroke treatment often involves tissue-type plasminogen activator (tPA) to restore blood flow.
• Edaravone, a free radical scavenger, is explored for its neuroprotective potential in stroke.
• Investigating combination therapy for acute ischemic stroke is crucial for improving patient outcomes.

Purpose of the Study:

• To determine if initiating edaravone before or during tPA enhances early recanalization in acute ischemic stroke.
• To evaluate the impact of edaravone timing on recanalization rates and clinical outcomes.
• To assess the safety profile of early versus delayed edaravone administration in conjunction with tPA.

Main Methods:

• The YAMATO study was a prospective, randomized, open-label, multicenter trial involving 165 patients with middle cerebral artery occlusion.
• Patients received tPA within 4.5 hours of stroke onset and were randomized to receive edaravone either before/during tPA (early group) or after tPA (late group).
• Primary outcome was early recanalization at 1.5 hours post-tPA; secondary outcomes included recanalization rates, symptomatic intracerebral hemorrhage, and functional outcome at 3 months.

Main Results:

• Early recanalization rates were identical in both groups (53%, P=1.000).
• No significant differences were observed in significant recanalization (≥50%), symptomatic intracerebral hemorrhage rates, or favorable functional outcomes at 3 months between the early and late edaravone groups.
• The incidence of symptomatic intracerebral hemorrhage was 5% in the early group and 2% in the late group (P=0.443).

Conclusions:

• The timing of edaravone administration relative to tPA does not influence early recanalization rates.
• Initiating edaravone before or during tPA therapy does not improve functional outcomes or increase the risk of symptomatic intracerebral hemorrhage.
• Current evidence suggests that the timing of edaravone infusion does not alter the efficacy or safety of tPA therapy for acute ischemic stroke.